We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
Pipeline
Ivaltinostat
-
Indication
Fibrotic diseases including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), chronic kidney diseases (CKD), Alport Syndrome, etc.
-
Development stage
Phase 1 clinical study for oral formulation in progress
Ivaltinostat
During the wound healing process of each organ, the connective tissue replaces the normal parenchyma extensively and continuously.
Fibrosis is, however, a disease where this process is dysfunctional and causes tissue remodeling and permanent scar formation, resulting in loss of organ-specific functions.
-
Immune cell activity to respond to organ damage caused by physical, chemical, or infection releases fibroblast-stimulating lytic factors such as PDGF, CTGF, and IL-10, including TGF-β.
-
Uncontrolled immune cell activity induces continuous fibroblast-stimulating lytic factor generation
-
Fibroblast hyperproliferation and hyperactivity
-
Fibroblast differentiation activity of myofibroblasts and increased production of fibrotic proteins (Fibronectin, Collagen, Vimentin)
-
Loss of organ function due to fibrotic protein accumulation
-
- Inhibition of immune cell lung migration
- Inhibition of inflammatory cytokine production through inhibition of angiotensinogen expression
- Inhibition of the production of TGF-β, a fibroblast stimulating lytic factor
- Inhibition of myofibroblast differentiation mechanism (Epithelial to Mesenchymal Transition)
- Inhibition of the production of fibrotic proteins (Fibronectin, Collagen, Vimentin)
-
01
Efficacy has been verified in various fibrosis models (PHMG, Bleomycin, UUO, DOCA) including Alport syndrome-like animal models.
-
02
Limited safety concerns based on results from a Phase 1 clinical study in healthy adults.
-
03
Completed development of oral formulation of ivaltinostat.
-
1.
Suh, S.H. et al. CG200745, a novel HDAC inhibitor, attenuates kidney fibrosis in a murine model of alport syndrome. Int. J. Mol. Sci. 21, 1473 (2020).
-
2.
Choi, H.S. et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Sci. Rep. 8, 11546 (2018).
-
3.
Bae, E.H. et al. Renoprotective effect of the histone deacetylase inhibitor CG200745 in DOCA-salt hypertensive rats. Int. J. Mol. Sci. 20, 508 (2019).
-
4.
Kim, Y.S. et al. The anti-fibrotic effects of CG-745, an HDAC inhibitor, in bleomycin and PHMG-induced mouse models. Molecules 24, 2792 (2019).